Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy

Basit Öğe Kaydı
dc.contributor.authorÇeltik, C
dc.contributor.authorAcunas, B
dc.contributor.authorÖner, N
dc.contributor.authorPala, Ö
dc.date.accessioned2024-06-12T11:09:10Z
dc.date.available2024-06-12T11:09:10Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate serum concentrations of neuron-specific enolase (NSE) as a marker of the severity of hypoxic ischemic encephalopathy (HIE) and to elucidate the relation among the concentrations of NSE, grade of HIE and short-term outcome. Forty-three asphyxiated full-term newborn infants who developed symptoms and signs of HIE (Group 1) and 29 full-term newborn infants with meconium-stained amniotic fluid but with normal physical examination (Group 2) were studied with serial neurological examination, Denver developmental screening test (DDST), electroencephalogram and computerized cerebral tomography (CT) for neurological follow-up. Thirty healthy infants were selected as the control group. In the patient groups, two blood samples were taken to measure NSE levels, one between 4 and 48 It and the other 5-7 days after birth. Serum NSE levels were significantly higher in infants with HIE compared to those infants in Group 2 and control group. The mean serum concentrations of the second samples decreased in all groups studied but they were significantly higher in Group I compared to those in Group 2. Serum NSE concentrations of initial samples were significantly higher in patients with stage III HIE than in those with stages 11 and I. The sensitivity and specificity values of serum NSE as a predictor of HIE of moderate or severe degree (cut-off value 40.0 mug/l) were 79 and 70%, respectively, and as a predictor of poor outcome (cut-off value 45.4 mug/l) were calculated as 84 and 70%, respectively. The predictive capacity of serum NSE concentrations for poor outcome seems to be better than predicting HIE of moderate or severe degree. However, earlier and/or CSF samples may be required to establish serum NSE as an early marker for the application of neuroprotective strategies. (C) 2004 Elsevier B.V. All rights reserved.en_US
dc.identifier.doi10.1016/j.braindev.2003.12.007
dc.identifier.endpage402en_US
dc.identifier.issn0387-7604
dc.identifier.issue6en_US
dc.identifier.pmid15275704en_US
dc.identifier.scopus2-s2.0-3242697894en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage398en_US
dc.identifier.urihttps://doi.org/10.1016/j.braindev.2003.12.007
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22694
dc.identifier.volume26en_US
dc.identifier.wosWOS:000223381500011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofBrain & Developmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeuron-Specific Enolaseen_US
dc.subjectPerinatal Asphyxiaen_US
dc.subjectHypoxic Ischemic Encephalopathyen_US
dc.subjectShort-Term Outcomeen_US
dc.subjectMyelin Basic-Proteinen_US
dc.subjectCerebrospinal-Fluiden_US
dc.subjectAsphyxiaen_US
dc.subjectBlooden_US
dc.titleNeuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu